Condition: Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor · Sponsor: Shanghai Junshi Bioscience Co., Ltd.
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
This description comes directly from the study's public registry record.
Xiaohong Ding, Master · 13602465823 · xiaohong_ding@junshipharma.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | Not Yet Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| The First Hospital of Jilin University | Changchun, Jilin, China | Not Yet Recruiting |
| Liaoning Cancer Hospital & Institute | Shenyang, Liaoning, China | Not Yet Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Yunnan Cancer Hospital | Kunming, Yunnan, China | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06839105